Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Intellectual Property Protection In China Improving In Incremental Stages - BioBusiness 2009 Conference

This article was originally published in PharmAsia News

Executive Summary

TAIPEI - China, generally thought to be a black hole for intellectual property, may be less dangerous for research-intensive pharmaceutical companies than is generally thought

You may also be interested in...

Pfizer Loses 'Weige' Trademark Suit

China's Supreme Court has given its final decision that upholds the original verdict of the 'Weige' trademark infringement case, rejecting Pfizer's appeal and putting an end to the company's 11-year trademark battle against Guangzhou Welman Pharmaceutical (PharmAsia News, April 14, 2008). According to Welman officials, China has an erectile dysfunction drug market worth tens of billions of renminbi but the combined revenue of the three-largest imported ED brands did not exceed RMB 100 million last year. The firm believes the non-standardized market has missed the best window of opportunity and will not be making a breakthrough in the short term. Welman evaluated the 'Weige' trademark to be worth some RMB 700 million ($102.5 million) and it does not discount collaborations with MNCs. (Click here for more - Chinese Language)

Newly Passed Chinese Patent Law Allows Government To Issue Compulsory Licenses On Patented Drugs

SHANGHAI - The Third Amendment of China's new Patent Laws passed by the 6th Session of the 11th Standing Committee of the National People's Congress on Dec. 27, means that the government can issue compulsory licenses on patented drugs in China, according to the new amendment

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts